- Liquid biopsy using extracellular vesicle–derived DNA in lung adenocarcinoma
-
In Ae Kim, Jae Young Hur, Hee Joung Kim, Seung Eun Lee, Wan Seop Kim, Kye Young Lee
-
J Pathol Transl Med. 2020;54(6):453-461. Published online October 8, 2020
-
DOI: https://doi.org/10.4132/jptm.2020.08.13
-
-
4,063
View
-
141
Download
-
8
Citations
-
 Abstract
 PDF
- Blood liquid biopsy has emerged as a way of overcoming the clinical limitations of repeat biopsy by testing for the presence of acquired resistance mutations to therapeutic agents. Despite its merits of repeatability and non-invasiveness, this method is currently only used as a supplemental test due to a relatively low sensitivity rate of 50%–60%, and cannot replace tissue biopsy. The circulating tumor DNAs used in blood liquid biopsies are passive products of fragmented DNA with a short half-life released following tumor cell death; the low sensitivity seen with liquid blood biopsy results from this instability, which makes increasing the sensitivity of this test fundamentally difficult. Extracellular vesicles (EVs) are ideal carriers of cancer biomarkers, as cancer cells secret an abundance of EVs, and the contents of tumor cell-originated EVs reflect the molecular and genetic composition of parental cells. In addition, EV-derived DNAs (EV DNAs) consist of large-sized genomic DNAs and tumor-specific oncogenic mutant DNAs. For these reasons, liquid biopsy using EV DNA has the potential to overcome issues arising from tissue shortages associated with small biopsies, which are often seen in lung cancer patients, and the biopsy product can be used in other diagnostic methods, such as epidermal growth factor receptor (EGFR) mutation testing and next-generation sequencing (NGS). A higher sensitivity can be achieved when EV DNAs obtained from bronchoalveolar lavage fluid (BALF) are used rather than those from blood. BALF, when obtained close to the tumor site, is a promising liquid biopsy tool, as it enables the gathering of both cellular and non-cellular fractions of the tumor microenvironment, and provides increased diagnostic sensitivity when compared to blood.
-
Citations
Citations to this article as recorded by  - Extracellular Vesicle-DNA: The Next Liquid Biopsy Biomarker for Early Cancer Diagnosis?
Irène Tatischeff
Cancers.2023; 15(5): 1456. CrossRef - In-Cell Labeling Coupled to Direct Analysis of Extracellular Vesicles in the Conditioned Medium to Study Extracellular Vesicles Secretion with Minimum Sample Processing and Particle Loss
Anissa Viveiros, Vaibhavi Kadam, John Monyror, Luis Carlos Morales, Desmond Pink, Aja M. Rieger, Simonetta Sipione, Elena Posse de Chaves
Cells.2022; 11(3): 351. CrossRef - Recent advances in liquid biopsy in cancers: Diagnosis, disease state and treatment response monitoring
Zhixian Chen, Judy Wai Ping Yam
Clinical and Translational Discovery.2022;[Epub] CrossRef - Cell-Secreted Vesicles: Novel Opportunities in Cancer Diagnosis, Monitoring and Treatment
Cristina Catoni, Veronica Di Paolo, Elisabetta Rossi, Luigi Quintieri, Rita Zamarchi
Diagnostics.2021; 11(6): 1118. CrossRef - DNA-Loaded Extracellular Vesicles in Liquid Biopsy: Tiny Players With Big Potential?
Susana García-Silva, Miguel Gallardo, Héctor Peinado
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef - Characteristics and Clinical Application of Extracellular Vesicle-Derived DNA
Jae Young Hur, Kye Young Lee
Cancers.2021; 13(15): 3827. CrossRef - Bronchoalveolar Lavage as a Potential Diagnostic Specimens to Genetic Testing in Advanced Lung Cancer
Xuwen Lin, Xueying Wang, Yazhou Cai, Chenyu Zong, Dawei Liu, Jiming Yu, Chenxin Zhou, Jing Yao, Zheng Li, ping xu
SSRN Electronic Journal .2021;[Epub] CrossRef - Multi-Omics Data Integration in Extracellular Vesicle Biology—Utopia or Future Reality?
Leona Chitoiu, Alexandra Dobranici, Mihaela Gherghiceanu, Sorina Dinescu, Marieta Costache
International Journal of Molecular Sciences.2020; 21(22): 8550. CrossRef
|
